Form 4: Alkermes Executive Sells 4,000 Shares in Pre-Planned Trade

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, sold 4,000 ordinary shares for $28 each under a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, Executive Vice President of Research & Development and Chief Medical Officer of Alkermes plc (ALKS), reported a sale of company shares.
• The transaction involved the disposition of 4,000 ordinary shares.
• The shares were sold at a price of $28 per share.
• The sale occurred on January 2, 2026.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hopkinson on March 14, 2025.
• Following this transaction, Mr. Hopkinson directly beneficially owns 61,740 ordinary shares of Alkermes plc.

Sentiment

Score: 5

Explanation: The sale of shares by an executive under a pre-arranged 10b5-1 plan is a routine disclosure and does not inherently signal positive or negative sentiment regarding the company's immediate prospects. It is a planned liquidity event.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for a publicly traded pharmaceutical company and does not inherently reflect broader industry trends or competitive positioning. It pertains specifically to an executive's personal stock management.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider sale, not typically indicative of new material information.

Key Dates

Recommendation

The sale of 4,000 shares by an executive, while notable, was conducted under a Rule 10b5-1 trading plan adopted well in advance (March 2025 for a January 2026 sale). This indicates a pre-scheduled liquidity event rather than a reaction to new material non-public information. As such, this single transaction does not provide sufficient grounds to alter an investment thesis or recommend a change from a 'hold' position without additional fundamental analysis.

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Stock Sale, Executive Compensation, Craig C. Hopkinson, 10b5-1 Plan, Pharmaceuticals, Biotech